The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always looking at the latest trends in value, growth, and momentum to find strong picks.Of these, perhaps no stock market trend is more popular than value investing, which is a strategy that has proven to be successful in all sorts of market environments. Value investors use a variety of methods, including tried-and-true v ...

Core Insights - CorMedix Therapeutics will present a corporate overview at the 44th annual J.P. Morgan Healthcare Conference on January 12, 2026, at 4:30pm PST [1][2] Company Overview - CorMedix Therapeutics is focused on developing and commercializing therapeutic products for life-threatening diseases and conditions [2] - The company is commercializing DefenCath® for the prevention of catheter-related bloodstream infections in adult patients undergoing hemodialysis via a central venous catheter [2] - Following the acquisition of Melinta Therapeutics LLC in August 2025, CorMedix is also commercializing a portfolio of anti-infective products, including MINOCIN®, REZZAYO®, VABOMERE®, ORBACTIV™, BAXDELA®, and KIMYRSA®, as well as TOPROL-XL® [2] Clinical Studies and Developments - CorMedix has ongoing clinical studies for DefenCath in Total Parenteral Nutrition (TPN) and Pediatric Hemodialysis populations [3] - The company intends to develop DefenCath as a catheter lock solution for use in other patient populations [3] - REZZAYO is currently approved for the treatment of candidemia and invasive candidiasis in adults, with an ongoing Phase III study for the prophylaxis of invasive fungal disease (IFD) in adult patients undergoing allogeneic bone marrow transplantation (BMT) [3] - Topline results of the Phase III study for REZZAYO are expected in Q2 2026 [3]

Truist Financial sets a new price target of $16 for CorMedix Therapeutics (NASDAQ:CRMD), indicating an 84.95% potential upside.CorMedix reports preliminary unaudited net revenue of $127 million for Q4 and $400 million for the full year of 2025.The company's adjusted EBITDA for Q4 is expected to be between $77 million and $81 million, showcasing strong operational performance.CorMedix Therapeutics, trading on the NASDAQ under the symbol CRMD, is a biopharmaceutical company focused on developing and commercia ...

Core Insights - The market has experienced significant price movements among various companies, indicating a mix of company-specific developments and broader market trends [1] Company-Specific Developments - John Hancock ESG Large Cap Core Fund Class A (JHJAX) saw a dramatic price drop to $12.56, reflecting a -42.01% change, potentially due to shifts in investor sentiment towards ESG investments [2][8] - Immuneering Corporation (IMRX) experienced a stock price decline to $4.92, a -40.94% change, likely influenced by market reactions to updates from its Phase 2a trial of atebimetinib for pancreatic cancer [3][8] - MSP Recovery, Inc. (MSPR) had its price decrease to $0.05, translating to a -38.29% change, with a notable increase in short interest indicating growing bearish sentiment among investors [4][8] - CorMedix Inc. (CRMD) saw a decrease to $7.43, a -33.47% change, possibly due to challenges related to its lead product candidate and recent leadership changes [5] - Locafy Limited (LCFYW) experienced a price drop to $3, a -31.03% change, which may be linked to updates on its technology platform and market positioning [6] Market Trends and Investor Sentiment - The significant trading volumes for these companies suggest active investor engagement, likely in response to recent announcements or broader market conditions [3][4][5][6] - Understanding the underlying causes of these price changes is crucial for investors, as they reflect the dynamic nature of the stock market influenced by clinical trial results, financial performance, and strategic shifts [7]

Investors are bailing on CorMedix (NASDAQ: CRMD) today after the biotech firm guided for up to $320 million in revenue for its fiscal 2026. The announcement isn't sitting well with shareholders, prima... ...

U.S. stocks traded mixed midway through trading, with the Dow Jones index gaining more than 250 points on Thursday.The Dow traded up 0.54% to 49,261.60 while the NASDAQ declined 0.62% to 23,437.73. The S&P 500 also fell, dropping, 0.05% to 6,917.76.Check This Out: Delta Air Lines Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings CallLeading and Lagging SectorsIndustrials shares gained by 1.4% on Thursday.In trading on Thursday, information technology stocks dipped by 1.4 ...

U.S. stocks traded lower this morning, with the Nasdaq Composite falling more than 100 points on Thursday.Following the market opening Thursday, the Dow traded down 0.05% to 48,972.29 while the NASDAQ declined 0.57% to 23,448.86. The S&P 500 also fell, dropping, 0.14% to 6,911.57.Check This Out: Delta Air Lines Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings CallLeading and Lagging SectorsIndustrials shares gained by 1.4% on Thursday.In trading on Thursday, information ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CORMEDIX INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-34673 20-5894890 (State or Other Jurisdiction (Commission File Number) (IRS Employer of Incorporation) Identification No.) CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 300 Connell Drive, Suite 4200 Berkeley Heights, New Jersey 07922 (Address of Principal Executive Offices) (Zip Code) Date of Report (Date of ...

BERKELEY HEIGHTS, N.J., Jan. 08, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced an addition to its executive leadership team and updates to its Board of Directors. CorMedix CEO Joseph Todisco has signed an extended employment contract, reaffirming his long-term commitment to the organization. In addition to his role as CEO, Mr. Todisco will ...

‒ Q4 2025 Unaudited Net Revenue of Approximately $127 million ‒ ‒ FY 2025 Unaudited Pro Forma Net Revenue of Approximately $400 million ‒ ‒ Expects Q4 Adjusted EBITDA of Between $77 million and $81 million ‒ ‒ Unaudited Cash and Short-term Investments of Approximately $148 million ‒ BERKELEY HEIGHTS, N.J., Jan. 08, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and condit ...